Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma.

Harada, Ken-Ichi; Miyake, Hideaki; Furukawa, Junya; Fujimoto, Naohiro; Fujisawa, Masato

Harada, Ken-Ichi; Miyake, Hideaki; Furukawa, Junya; Fujimoto, Naohiro; Fujisawa, Masato.

Afiliação

Harada KI; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Miyake H; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Furukawa J; Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Fujimoto N; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Fujisawa M; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.

Int J Urol ; 29(8): 816-822, 2022 08.

Article em En | MEDLINE | ID: mdl-35636920

Assuntos

Antineoplásicos; Carcinoma de Células Renais; Neoplasias Renais; Antineoplásicos/uso terapêutico; Carcinoma de Células Renais/patologia; Humanos; Imunoterapia; Neoplasias Renais/patologia; Prognóstico

Palavras-chave

advanced renal cell carcinoma; combination therapy; first-line treatment; immuno-oncology drugs; prognostic outcome

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Antineoplásicos Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Int J Urol Assunto da revista: UROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google